Stem Cell Clinic

Sumit Dewanjee, MD, is being recognized by Continental Who’s Who – PRNewswire

TEMPE, Ariz., May 7, 2020 /PRNewswire/ --Sumit Dewanjee, MD, is being recognized by Continental Who's Who as a Top Orthopedic Surgeon in the field of medicine as an at FXRX Orthopedics and Bracing.

Serving patients in the metropolitan Phoenix, Arizona area FXRX is the leading practice in Arizona for orthopedic surgery. FXRX mainly focuses on orthopedic sports injuries of the hip, knee, and shoulder, along with orthopedic fracture treatments such as stem cell therapy and cartilage restoration procedures.

Dr. Sumit Dewanjee is the founder and premier Board-certified Orthopedic Surgeon at FXRX with 16 years' experience in orthopedic surgery. His particular areas of focus are knee and shoulder surgery, fracture treatment and he's knowledgeable in both general orthopedics and orthopedic bracing. His additional skills include performing minimally invasive procedures using arthroscopy, with expertise in minimizing blood loss and patient recovery periods while providing the results and benefits of advanced and cutting edge treatments in surgery.

To gain the knowledge needed for his successful career with his private practice, Dr. Dewanjee attended the University of Miami and received his Medical Degree followed by Maricopa Medical Center to complete his residency.

In addition to his affiliations with MENSA, American Academy Ortho Surgeons, Dr. Dewanjee has been awarded the Patient Choice Award for the 7th time, maintaining his status as one of the best orthopedic surgeons in Phoenix, AZ. and Compassionate Doctors.

During his free time, Dr. Dewanjee donates to The Human Society.

Dr. Dewanjee dedicates his success to his mentor Dr. Dana Seltzer.

For more information please visit fxrxinc.com

Contact: Katherine Green , 516-825-5634 [emailprotected]

SOURCE Continental Who's Who

http://www.continentalwhoswho.com

Excerpt from:
Sumit Dewanjee, MD, is being recognized by Continental Who's Who - PRNewswire

Results From Pivotal Phase 2/3 Study of Emapalumab in Patients With Primary HLH Published in New England Journal of Medicine – BioSpace

STOCKHOLM, May 7, 2020 /PRNewswire/ -- Sobi announced today that the results from the pivotal phase 2/3 study evaluating the efficacy and safety of emapalumab in patients with primary haemophagocytic lymphohistiocytosis (HLH) were published in the New England Journal of Medicine on 7 May 2020. Emapalumab is the first therapy approved by the US Food & Drug Administration (FDA) for primary HLH and is under review by the European Medicines Agency (EMA).

Primary HLH is a rare syndrome that typically presents in infancy but can also be seen in adults and is associated with high morbidity and mortality. This life-threatening disease is characterised by immune dysregulation and uncontrolled hyperinflammation. The treatment objective is to suppress the hyperinflammation and control the acute features of the disease in order to successfully bring patients to haematopoietic stem cell transplantation (HSCT).

"The publication of the results in this highly respected medical journal is a testament to the medical importance of the emapalumab findings for patients with primary HLH," says Milan Zdravkovic, Head of Research & Development and Chief Medical Officer at Sobi. "The results further advance our understanding of primary HLH and the role of interferon gamma in its pathogenesis. Our hope is to contribute to the improvement of care and treatment for patients suffering from this potentially fatal disease."

The results with emapalumab in primary HLH published in the New England Journal of Medicine highlight the overall response rate of 63 percent in previously treated patients at the end of up to 8 weeks of treatment (compared to the pre-specified null hypothesis of 40 percent (p=0.02)). In the previously treated group, 70 percent of patients were able to proceed to transplantation. The most commonly reported adverse reactions ( 20 per cent) were infections, hypertension, infusion-related reactions and fever.

Michael Jordan, Professor of Pediatrics at the Cincinnati Children's Hospital Medical Center in the US and coordinating Principal Investigator of the study (US), confirms the importance of making advances in finding new therapies for HLH and emphasises the importance of the publication of the results: "The findings from the study are encouraging for those affected by this devastating disease."

Professor Franco Locatelli, Head of the Department of Onco-Haematology, Bambino Ges Children's Hospital IRCCS, Sapienza University of Rome, Italy, and coordinating Principal Investigator (EU), adds: "Emapalumab represents a prototype model molecularly targeted therapy and an important step towards improving outcomes for this severe and life-threatening disease."

This pivotal clinical study is the first study in primary HLH to prospectively assess and report treatment responses using predefined comprehensive objective clinical and laboratory criteria. Preclinical data have shown the central role of interferon gamma (IFN) in the pathogenesis of this disease1. Emapalumab is a monoclonal antibody that binds to and neutralises IFN. It was approved by the US Food & Drug Administration (FDA) on the basis of this clinical study for the treatment of primary HLH in adult and paediatric (newborn and older) patients with refractory, recurrent or progressive disease, or intolerance to conventional HLH therapy, and received Breakthrough Designation prior to review.

About emapalumab

Emapalumab is a monoclonal antibody that binds to and neutralises interferon gamma (IFN). In the US, emapalumab is indicated for paediatric (newborn and older) and adult primary haemophagocytic lymphohistiocytosis (HLH) patients with refractory, recurrent or progressive disease, or intolerance to conventional HLH therapy. Emapalumab is the first and only medicine approved in the US for primary HLH, a rare syndrome of hyperinflammation that usually occurs within the first year of life and can rapidly become fatal unless diagnosed and treated. The FDA approval is based on data from the phase 2/3 studies (NCT01818492 and NCT02069899). Emapalumab is indicated for administration through intravenous infusion over one hour twice per week until haematopoietic stem cell transplantation (HSCT). For more information please see http://www.gamifant.com including the full US Prescribing Information. Emapalumab is under review for primary HLH by the European Medicines Agency (EMA).

About SobiTM

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, Sobi employs approximately 1,400 people across Europe, North America, the Middle East, Russia and North Africa. In 2019, Sobi's revenues amounted to SEK 14.2 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at sobi.com.

For more information please contactPaula Treutiger, Head of Communication & Investor Relations+ 46-733-666-599paula.treutiger@sobi.com

Linda Holmstrm,Corporate Communication & Investor Relations+46-708-734-095linda.holmstrom@sobi.com

1. Jordan et al. Blood 2004;104:735-43.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/swedish-orphan-biovitrum-ab/r/results-from-pivotal-phase-2-3-study-of-emapalumab-in-patients-with-primary-hlh-published-in-new-eng,c3105820

The following files are available for download:

View original content:http://www.prnewswire.com/news-releases/results-from-pivotal-phase-23-study-of-emapalumab-in-patients-with-primary-hlh-published-in-new-england-journal-of-medicine-301054583.html

SOURCE Swedish Orphan Biovitrum AB

Company Codes: Berlin:B6E, Bloomberg:SOBI@SS, ISIN:SE0000872095, LSE:0MTD, OTC-PINK:BIOVF, RICS:SOBI.ST, Stockholm:SOBI, Dusseldorf:B6E, Frankfurt:B6E, Stuttgart:B6E

Read more:
Results From Pivotal Phase 2/3 Study of Emapalumab in Patients With Primary HLH Published in New England Journal of Medicine - BioSpace

COVID-19 Impact and Recovery Analysis | Global Cell Isolation Market 2020-2024 | Evolving Opportunities with Agilent Technologies Inc. and Becton,…

LONDON--(BUSINESS WIRE)--The global cell isolation market size is expected to grow by USD 9.47 billion as per Technavio. This marks a significant market growth compared to the 2019 growth estimates due to the impact of the COVID-19 pandemic in the first half of 2020. Moreover, steady growth is expected to continue throughout the forecast period, and the market is expected to grow at a CAGR of almost 21%.

Request for Technavio's latest reports on directly and indirectly impacted markets

Market estimates include pre- and post-COVID-19 impact on the cell isolation market -

Download free sample report

With the spread of COVID-19, a global increase in R&D activities in AR and PB has been observed in the first half of 2020. Researches are being conducted on stem cell therapies to develop mesenchymal stem cell-based therapies. For instance, in March 2020, researchers from the University of North Texas Health Science Center initiated a clinical trial in China on more than 100 COVID-19 patients and administered injections of mesenchymal stem cells. The rise in such R&D activities is increasing the demand for cell isolation products, which will result in the growth of the cell isolation market during the forecast period.

Technavio's custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations.

https://www.technavio.com/report/global-cell-isolation-market-industry-analysis

The market is driven by the increasing prevalence of chronic diseases. In addition, product advances are anticipated to boost the growth of the cell isolation market.

With the growing incidence of chronic diseases globally, the applications of isolated human cells in research, drug development, and clinical trials are increasing. Cell isolation helps study the behavior of cells and their response to diseases and different drugs. Cell isolation tools are used in drug discovery to generate recombinant protein therapeutics, which can treat a variety of chronic diseases. Hence, the rising prevalence of chronic diseases will boost the need for cell-based therapies, which, in turn, will increase the demand for cell isolation tools.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Cell Isolation Companies:

Agilent Technologies Inc.

Agilent Technologies Inc. has business operations under various segments, such as life sciences and applied markets, diagnostics and genomics, and Agilient CrossLab. The company offers various consumables and instruments for cell isolation procedures.

Becton, Dickinson and Co.

Becton, Dickinson and Co. operates its business through various segments, such as BD Medical, BD Life Sciences, and BD Interventional. The company provides consumables and instruments for cell isolation procedures.

Bio-Rad Laboratories Inc.

Bio-Rad Laboratories Inc. has business operations under two segments: life science and clinical diagnostics. The company provides consumables and instruments for cell isolation procedures.

Danaher Corp.

Danaher Corp. operates its business through various segments, such as life sciences, diagnostics, and environment & applied solutions. The company provides consumables and instruments for cell isolation procedures.

F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche Ltd. has business operations under two segments: pharmaceuticals and diagnostics. The company provides consumables and instruments for cell isolation procedures.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Cell Isolation Market Product Outlook (Revenue, USD bn, 2020-2024)

Cell Isolation Market Geography Outlook (Revenue, USD bn, 2020-2024)

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

View post:
COVID-19 Impact and Recovery Analysis | Global Cell Isolation Market 2020-2024 | Evolving Opportunities with Agilent Technologies Inc. and Becton,...

Stem Cell Alopecia Treatment Market Detailed Analysis of Current Industry Figures With Forecasts Growth by 2026 – 3rd Watch News

Stem Cell Alopecia Treatment Market Trends, Size, Shares, Growth, Top Companies, Development, Application, Importance, Overview with Detailed Analysis, Production, Supply, Revenue, Regional Outlook, Status, Competitive Landscape, Future Forecast, Type and End-User, Opportunity, Demand, Historical Data, Business Insights, Research Methodology and many more

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Stem Cell Alopecia Treatment Market which would mention How the Covid-19 is Affecting the Stem Cell Alopecia Treatment Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Covid-19 Impact on Key Regions and Proposal for Stem Cell Alopecia Treatment Players to Combat Covid-19 Impact.

Stem Cell Alopecia Treatment research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers, and challenges.

Top Key Players of the Global Stem Cell Alopecia Treatment Market:APEX Biologix, Belgravia Center, Kerastem, Riken Research Institute, RepliCel, Sanford Burnham Prebys Medical Discovery Institute,

Download Full PDF Sample Copy of Stem Cell Alopecia Treatment Report: (Including Full TOC, List of Tables & Figures, Chart) : https://www.qyresearch.com/sample-form/form/1491764/global-stem-cell-alopecia-treatment-market

Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.

* Top Key Company Profiles.* Main Business and Rival Information* SWOT Analysis and PESTEL Analysis* Production, Sales, Revenue, Price and Gross Margin* Market Share and Size

Global Stem Cell Alopecia Treatment Market is estimated to reach xxx million USD in 2019 and projected to grow at the CAGR of xx% during 2019-2025. According to the latest report added to the online repository of QY Research the Stem Cell Alopecia Treatment market has witnessed an unprecedented growth till 2019. The extrapolated future growth is expected to continue at higher rates by 2025.

Stem Cell Alopecia Treatment Market Size Estimation

Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).

The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.

Get Full Customize report now at: https://www.qyresearch.com/customize-request/form/1491764/global-stem-cell-alopecia-treatment-market

Critical questions addressed by the Stem Cell Alopecia Treatment Market report

What are the key market drivers and restraints?What will be the market size until the end of the forecast period?Which segment is expected to take the lions share?Which region will lead the global Stem Cell Alopecia Treatment market in terms of growth?What will be the key strategies adopted by market leaders in future?What are the upcoming applications?How will the global Stem Cell Alopecia Treatment market develop in the mid to long term?

Table of Contents

1 Stem Cell Alopecia Treatment Market Overview1.1 Stem Cell Alopecia Treatment Product Overview1.2 Stem Cell Alopecia Treatment Market Segment by Type1.2.1 Cloud Service Orchestration1.2.2 API Management1.2.3 Application Integration1.2.4 B2B and Cloud Integration1.2.5 Data Integration1.3 Global Stem Cell Alopecia Treatment Market Size by Type1.3.1 Global Stem Cell Alopecia Treatment Sales and Growth by Type1.3.2 Global Stem Cell Alopecia Treatment Sales and Market Share by Type (2014-2019)1.3.3 Global Stem Cell Alopecia Treatment Revenue and Market Share by Type (2014-2019)1.3.4 Global Stem Cell Alopecia Treatment Price by Type (2014-2019)

2 Global Stem Cell Alopecia Treatment Market Competition by Company2.1 Global Stem Cell Alopecia Treatment Sales and Market Share by Company (2014-2019)2.2 Global Stem Cell Alopecia Treatment Revenue and Share by Company (2014-2019)2.3 Global Stem Cell Alopecia Treatment Price by Company (2014-2019)2.4 Global Top Players Stem Cell Alopecia Treatment Manufacturing Base Distribution, Sales Area, Product Types2.5 Stem Cell Alopecia Treatment Market Competitive Situation and Trends2.5.1 Stem Cell Alopecia Treatment Market Concentration Rate2.5.2 Global Stem Cell Alopecia Treatment Market Share of Top 5 and Top 10 Players2.5.3 Mergers & Acquisitions, Expansion

3 Stem Cell Alopecia Treatment Company Profiles and Sales Data3.1 IBM3.1.1 Company Basic Information, Manufacturing Base and Competitors3.1.2 Stem Cell Alopecia Treatment Product Category, Application and Specification3.1.3 IBM Stem Cell Alopecia Treatment Sales, Revenue, Price and Gross Margin(2014-2019)3.1.4 Main Business Overview3.2 Microsoft3.2.1 Company Basic Information, Manufacturing Base and Competitors3.2.2 Stem Cell Alopecia Treatment Product Category, Application and Specification3.2.3 Microsoft Stem Cell Alopecia Treatment Sales, Revenue, Price and Gross Margin(2014-2019)3.2.4 Main Business Overview3.3 Oracle3.3.1 Company Basic Information, Manufacturing Base and Competitors3.3.2 Stem Cell Alopecia Treatment Product Category, Application and Specification3.3.3 Oracle Stem Cell Alopecia Treatment Sales, Revenue, Price and Gross Margin(2014-2019)3.3.4 Main Business Overview3.4 Software3.4.1 Company Basic Information, Manufacturing Base and Competitors3.4.2 Stem Cell Alopecia Treatment Product Category, Application and Specification3.4.3 Software Stem Cell Alopecia Treatment Sales, Revenue, Price and Gross Margin(2014-2019)3.4.4 Main Business Overview3.5 TIBCO Software3.5.1 Company Basic Information, Manufacturing Base and Competitors3.5.2 Stem Cell Alopecia Treatment Product Category, Application and Specification3.5.3 TIBCO Software Stem Cell Alopecia Treatment Sales, Revenue, Price and Gross Margin(2014-2019)3.5.4 Main Business Overview3.6 Accenture3.6.1 Company Basic Information, Manufacturing Base and Competitors3.6.2 Stem Cell Alopecia Treatment Product Category, Application and Specification3.6.3 Accenture Stem Cell Alopecia Treatment Sales, Revenue, Price and Gross Margin(2014-2019)3.6.4 Main Business Overview3.7 Adeptia3.7.1 Company Basic Information, Manufacturing Base and Competitors3.7.2 Stem Cell Alopecia Treatment Product Category, Application and Specification3.7.3 Adeptia Stem Cell Alopecia Treatment Sales, Revenue, Price and Gross Margin(2014-2019)3.7.4 Main Business Overview3.8 Atos3.8.1 Company Basic Information, Manufacturing Base and Competitors3.8.2 Stem Cell Alopecia Treatment Product Category, Application and Specification3.8.3 Atos Stem Cell Alopecia Treatment Sales, Revenue, Price and Gross Margin(2014-2019)3.8.4 Main Business Overview3.9 Axway3.9.1 Company Basic Information, Manufacturing Base and Competitors3.9.2 Stem Cell Alopecia Treatment Product Category, Application and Specification3.9.3 Axway Stem Cell Alopecia Treatment Sales, Revenue, Price and Gross Margin(2014-2019)3.9.4 Main Business Overview3.10 BT Global Services3.10.1 Company Basic Information, Manufacturing Base and Competitors3.10.2 Stem Cell Alopecia Treatment Product Category, Application and Specification3.10.3 BT Global Services Stem Cell Alopecia Treatment Sales, Revenue, Price and Gross Margin(2014-2019)3.10.4 Main Business Overview

4 Stem Cell Alopecia Treatment Market Status and Outlook by Regions4.1 Global Market Status and Outlook by Regions4.1.1 Global Stem Cell Alopecia Treatment Market Size and CAGR by Regions4.1.2 North America4.1.3 Asia-Pacific4.1.4 Europe4.1.5 South America4.1.6 Middle East and Africa4.2 Global Stem Cell Alopecia Treatment Sales and Revenue by Regions4.2.1 Global Stem Cell Alopecia Treatment Sales and Market Share by Regions (2014-2019)4.2.2 Global Stem Cell Alopecia Treatment Revenue and Market Share by Regions (2014-2019)4.2.3 Global Stem Cell Alopecia Treatment Sales, Revenue, Price and Gross Margin (2014-2019)4.3 North America Stem Cell Alopecia Treatment Sales, Revenue, Price and Gross Margin4.3.1 United States4.3.2 Canada4.3.3 Mexico4.4 Europe Stem Cell Alopecia Treatment Sales, Revenue, Price and Gross Margin4.4.1 Germany4.4.2 UK4.4.3 France4.4.4 Italy4.4.5 Russia4.4.6 Turkey4.5 Asia-Pacific Stem Cell Alopecia Treatment Sales, Revenue, Price and Gross Margin4.5.1 China4.5.2 Japan4.5.3 Korea4.5.4 Southeast Asia4.5.4.1 Indonesia4.5.4.2 Thailand4.5.4.3 Malaysia4.5.4.4 Philippines4.5.4.5 Vietnam4.5.5 India4.5.6 Australia4.6 South America Stem Cell Alopecia Treatment Sales, Revenue, Price and Gross Margin4.6.1 Brazil4.7 Middle East and Africa Stem Cell Alopecia Treatment Sales, Revenue, Price and Gross Margin4.7.1 Egypt4.7.2 GCC Countries

5 Stem Cell Alopecia Treatment Application/End Users5.1 Stem Cell Alopecia Treatment Segment by Application5.1.1 Banking, Financial Services, and Insurance5.1.2 Consumer Goods and Retail5.1.3 Education5.1.4 Government and Public Sector5.1.5 Healthcare and Life Sciences5.1.6 Manufacturing5.1.7 Media and Entertainment5.1.8 Telecommunication and Ites5.1.9 Others5.2 Global Stem Cell Alopecia Treatment Product Segment by Application5.2.1 Global Stem Cell Alopecia Treatment Sales by Application5.2.2 Global Stem Cell Alopecia Treatment Sales and Market Share by Application (2014-2019)

6 Global Stem Cell Alopecia Treatment Market Forecast6.1 Global Stem Cell Alopecia Treatment Sales, Revenue Forecast (2019-2025)6.1.1 Global Stem Cell Alopecia Treatment Sales and Growth Rate Forecast (2019-2025)6.1.1 Global Stem Cell Alopecia Treatment Revenue and Growth Rate Forecast (2019-2025)6.2 Global Stem Cell Alopecia Treatment Forecast by Regions6.2.1 North America Stem Cell Alopecia Treatment Sales and Revenue Forecast (2019-2025)6.2.2 Europe Stem Cell Alopecia Treatment Sales and Revenue Forecast (2019-2025)6.2.3 Asia-Pacific Stem Cell Alopecia Treatment Sales and Revenue Forecast (2019-2025)6.2.3.1 China6.2.3.2 Japan6.2.3.3 Korea6.2.3.4 Southeast Asia6.2.3.5 India6.2.3.6 Australia6.2.4 South America Stem Cell Alopecia Treatment Sales and Revenue Forecast (2019-2025)6.2.5 Middle East and Africa Stem Cell Alopecia Treatment Sales and Revenue Forecast (2019-2025)6.2.5.1 Egypt6.2.5.2 GCC Countries6.3 Stem Cell Alopecia Treatment Forecast by Type6.3.1 Global Stem Cell Alopecia Treatment Sales and Revenue Forecast by Type (2019-2025)6.3.2 Cloud Service Orchestration Gowth Forecast6.3.3 API Management Gowth Forecast6.4 Stem Cell Alopecia Treatment Forecast by Application6.4.1 Global Stem Cell Alopecia Treatment Sales Forecast by Application (2019-2025)6.4.2 Global Stem Cell Alopecia Treatment Forecast in Banking, Financial Services, and Insurance6.4.3 Global Stem Cell Alopecia Treatment Forecast in Consumer Goods and Retail

7 Stem Cell Alopecia Treatment Upstream Raw Materials7.1 Stem Cell Alopecia Treatment Key Raw Materials7.1.1 Key Raw Materials7.1.2 Key Raw Materials Price7.1.3 Raw Materials Key Suppliers7.2 Manufacturing Cost Structure7.2.1 Raw Materials7.2.2 Labor Cost7.2.3 Manufacturing Expenses7.3 Stem Cell Alopecia Treatment Industrial Chain Analysis

8 Marketing Strategy Analysis, Distributors8.1 Marketing Channel8.1.1 Direct Marketing8.1.2 Indirect Marketing8.1.3 Marketing Channel Development Trend8.2 Distributors8.3 Downstream Customers

9 Research Findings and Conclusion

AppendixMethodology/Research ApproachResearch Programs/DesignMarket Size EstimationMarket Breakdown and Data TriangulationData SourceSecondary SourcesPrimary SourcesDisclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Originally posted here:
Stem Cell Alopecia Treatment Market Detailed Analysis of Current Industry Figures With Forecasts Growth by 2026 - 3rd Watch News

AMC to use stem cell therapy in treating graft-versus-host disease – Korea Biomedical Review

Korean researchers have found a signal transduction system that modulates the treatment of mesenchymal stem cells and immune control functions, opening the way for treating graft-versus-host disease treatment.

Mesenchymal stem cells divide into various cells, have immunomodulatory functions, and are the primary cell sources for stem cell therapy.

Graft-versus-host disease is a fatal disease that leads to death after an allogeneic blood transfusion or bone marrow transplantation. Although there are many clinical trials underway worldwide to treat the symptom, there are no applicable treatments besides alleviating symptoms with high-dose steroids.

The team, led by Professor Shin Dong-myeong of the Department of Biomedical Sciences at Asan Medical Center, discovered that the CREB1 (CAMP responsive element binding protein 1) signaling system activates the treatment and immune control functions of mesenchymal stem cells.

The team administered a therapeutic agent made by upgrading mesenchymal stem cells to graft-versus-host disease mice, and found that it alleviated anorexia symptoms and reduced the weight loss rate by 30 percent while increasing the survival rate by 30 percent.

When developing a cell therapy product, researchers have to cultivate the stem cells in vitro. Thus it is very likely that it will impair stem cell functions due to free radicals generated in the cells. To prevent the deterioration of stem cell function, it is necessary to improve the stem cell function in vitro culture, prevent stem cell oxidation, and increase the antioxidant capacity of the cell itself.

Until now, there was a lack of specific evidence and understanding of how stem cells regulate glutathione, an indicator of antioxidant capacity. Therefore, it was difficult to prevent stem cell dysfunction and oxidation.

Professor Shin's team developed experimental techniques that can monitor and quantify glutathione in real-time and confirmed that the CREB1 signaling system regulated the amount and activity of glutathione.

By activating the CREB1 signaling system, the team found that the process also activated nuclear factor erythroid 2-related factor 2 (NRF2) protein, which maintains the antioxidant capacity of mesenchymal stem cells and the increase of both the expression levels of peroxiredoxin-1 (PRDX1) and glutamate-cysteine ligase modifier subunit (GCLM) protein, which synthesize glutathione and are antioxidant activity indicators.

As a result, the team confirmed that its method was effective in treating the graft-versus-host disease.

"Based on this study, we have secured a technological foundation to advance stem cell treatment by controlling the antioxidant capacity of stem cells," Professor Shin said.

If this technology makes a high-purity and high-quality stem cell treatment, the team expects that it will be a step toward developing a graft-versus-host disease treatment and overcoming various intractable diseases such as nervous system diseases and inflammatory diseases with high medical demand, Shin added.

The results of the study were published in the journal, Science Advances.

corea022@docdocdoc.co.kr

< Korea Biomedical Review, All rights reserved.>

Read the original here:
AMC to use stem cell therapy in treating graft-versus-host disease - Korea Biomedical Review

Drumming class finds a new rhythm with creative connections – Yes! Weekly

Winston-Salem, N.C. When music professor John Becks Afro-Cuban drumming class moved online, his students didnt miss a beat even though only one of the 17 seniors in his class had access to a drum.

The global drum circle community on social media was quick to offer ideas for virtual groups. One video showed a friend of mine drumming on a picnic table and asking people to play his rhythm back, said Beck.

The students first assignment was based on that video.

I assembled their clips together and posted the recording so they could all see each other like we do in class when we are seated in a circle. One week I asked the students to send me their favorite song, and they recorded themselves drumming on buckets, tables, boxes and metal pots.

In an in-person class there is a sense of community, Beck explains. The group works together creating rhythm, smiling and enjoying the experience. But after spending time immersed in the video projects, looking at the student clips, watching them drum and assembling the projects on his computer, he felt he knew this class better than any other he has taught.

Beck recently completed a 22-month study at Wake Forest Baptist Medical Center with stem cell transplant recipients using a protocol developed called Comfort Sound drumming. During the patient drumming experience, researchers identified improvement in mood, energy and relaxation, and decreases in anxiety, distress and pain.

The video compilations were a way of being together through the music and my students expressed they felt similar benefits to the ones in our study. Our work together helped them cope with the stress of finishing their time at Wake Forest away from their friends and teachers.

Senior Lizzie Pittinger, a political science major, said continuing with the drumming exercises online was not only a fun way to stay connected with her classmates, but also created a sense of normalcy during this uncertain time. Despite the physical distance that I felt from my classmates as we were all learning from our own homes, the weekly assignments reminded me that we will always be able to connect by sharing experiences with each othereven if it has to be through Zoom for now!

Watch the video here.

###

About Wake Forest University:

Wake Forest University combines the best traditions of a small liberal arts college with the resources of a large research university. Founded in 1834, the school is located in Winston-Salem, N.C. The Universitys graduate school of arts and sciences, divinity school, and nationally ranked schools of law, medicine and business enrich our intellectual environment. Learn more about Wake Forest University at http://www.wfu.edu.

See the original post here:
Drumming class finds a new rhythm with creative connections - Yes! Weekly